Last updated on: September 9, 2021
Antisecretory drugs are used in the treatment and prophylaxis of peptic ulcer disease (below) some are also employed in other disorders associated with gastric hyperacidity such as gastro-oesophageal reflux disease and dyspepsia (below). They may be divided into:
- Histamine H2-receptor antagonists (H2-antagonists), which act by blocking histamine H2-receptors on gastric parietal cells, thereby antagonising the normal stimulatory effect of endogenous histamine on gastric acid production. Those described in mis site include cimeti-dine, famotidine, nizatidine, and ranitidine.
- Proton pump inhibitors, which act by blocking the enzyme system responsible for active transport of protons into the gastrointestinal lumen, namely the hydrogen/potassium adenosine triphosphatase (H+/K+ ATPase) of the gastric parietal cell, also known as the ‘proton pump’. Those described in mis site include lansoprazole, omeprazole, pantoprazole, and rabepra-zole.
- Selective antimuscarinics, which block cholinergic stimulation of gastric acid production with fewer adverse effects than less selective antimuscarinics (see Atropine), but have largely been superseded. Pirenzepine is an example.
- Prostaglandin analogues, which inhibit gastric acid secretion by a direct action on the parietal cell and may also inhibit gastrin release and possess cytoprotective properties. Misoprostol is an example.
Described in this site are:
- Cimetidine
- Ebrotidine
- Eseridine Salicylate
- Esomeprazole
- Famotidine
- Lafutidine
- Lansoprazole
- Niperotidine
- Nizatidine
- Omeprazole
- Pantoprazole
- Rabeprazole
- Ranitidine Bismuth Citrate
- Ranitidine
- Revaprazan
- Roxatidine
- Urogastrone